Preventing and managing the toxicities associated with the combination therapy of ibrutinib and venetoclax in chronic lymphocytic leukaemia
The combination of ibrutinib and venetoclax represents the first fixed-duration oral treatment involving a Bruton tyrosine kinase inhibitor and a BCL2 inhibitor for adult patients with untreated chronic lymphocytic leukaemia. The phase 2 CAPTIVATE and phase 3 GLOW clinical studies served as the basi...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Via Medica
2025-01-01
|
| Series: | Acta Haematologica Polonica |
| Subjects: | |
| Online Access: | https://journals.viamedica.pl/acta_haematologica_polonica/article/view/105572 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849232983939088384 |
|---|---|
| author | Elżbieta Iskierka-Jażdżewska Krzysztof Jamroziak Tadeusz Robak Bartosz Puła |
| author_facet | Elżbieta Iskierka-Jażdżewska Krzysztof Jamroziak Tadeusz Robak Bartosz Puła |
| author_sort | Elżbieta Iskierka-Jażdżewska |
| collection | DOAJ |
| description | The combination of ibrutinib and venetoclax represents the first fixed-duration oral treatment involving a Bruton tyrosine kinase inhibitor and a BCL2 inhibitor for adult patients with untreated chronic lymphocytic leukaemia. The phase 2 CAPTIVATE and phase 3 GLOW clinical studies served as the basis for this approval. This combination demonstrates high efficacy, a limited duration of therapy, and a tolerable adverse event profile. However, some concerns have been raised regarding its tolerability based on the results of clinical trials. The risk of developing adverse events may be minimised by careful selection of patients, including preventive measures and rational management of therapy-associated toxicities. Therefore, we have summarised the published data from clinical trials and real-world observations to optimise the treatment outcomes and tolerability of the ibrutinib and venetoclax combination. |
| format | Article |
| id | doaj-art-92761cfe36f3408c895afd6cf8e4c6d2 |
| institution | Kabale University |
| issn | 0001-5814 2300-7117 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Via Medica |
| record_format | Article |
| series | Acta Haematologica Polonica |
| spelling | doaj-art-92761cfe36f3408c895afd6cf8e4c6d22025-08-20T14:28:39ZengVia MedicaActa Haematologica Polonica0001-58142300-71172025-01-0156310.5603/ahp.105572Preventing and managing the toxicities associated with the combination therapy of ibrutinib and venetoclax in chronic lymphocytic leukaemiaElżbieta Iskierka-Jażdżewska0https://orcid.org/0000-0003-2772-8870Krzysztof Jamroziak1https://orcid.org/0000-0002-3411-6357Tadeusz Robak2https://orcid.org/0000-0002-3411-6357Bartosz Puła3https://orcid.org/0000-0003-0116-5002Department of General Haematology, Copernicus Memorial Hospital, Lodz, PolandDepartment of Haematology, Transplantation and Internal Medicine, Medical University of Warsaw, Warsaw, PolandDepartment of General Haematology, Copernicus Memorial Hospital, Lodz, PolandDepartment of General Haematology, Copernicus Memorial Hospital, Lodz, PolandThe combination of ibrutinib and venetoclax represents the first fixed-duration oral treatment involving a Bruton tyrosine kinase inhibitor and a BCL2 inhibitor for adult patients with untreated chronic lymphocytic leukaemia. The phase 2 CAPTIVATE and phase 3 GLOW clinical studies served as the basis for this approval. This combination demonstrates high efficacy, a limited duration of therapy, and a tolerable adverse event profile. However, some concerns have been raised regarding its tolerability based on the results of clinical trials. The risk of developing adverse events may be minimised by careful selection of patients, including preventive measures and rational management of therapy-associated toxicities. Therefore, we have summarised the published data from clinical trials and real-world observations to optimise the treatment outcomes and tolerability of the ibrutinib and venetoclax combination.https://journals.viamedica.pl/acta_haematologica_polonica/article/view/105572chronic lymphocytic leukaemiavenetoclaxibrutinibcardiovascular eventsneutropenia |
| spellingShingle | Elżbieta Iskierka-Jażdżewska Krzysztof Jamroziak Tadeusz Robak Bartosz Puła Preventing and managing the toxicities associated with the combination therapy of ibrutinib and venetoclax in chronic lymphocytic leukaemia Acta Haematologica Polonica chronic lymphocytic leukaemia venetoclax ibrutinib cardiovascular events neutropenia |
| title | Preventing and managing the toxicities associated with the combination therapy of ibrutinib and venetoclax in chronic lymphocytic leukaemia |
| title_full | Preventing and managing the toxicities associated with the combination therapy of ibrutinib and venetoclax in chronic lymphocytic leukaemia |
| title_fullStr | Preventing and managing the toxicities associated with the combination therapy of ibrutinib and venetoclax in chronic lymphocytic leukaemia |
| title_full_unstemmed | Preventing and managing the toxicities associated with the combination therapy of ibrutinib and venetoclax in chronic lymphocytic leukaemia |
| title_short | Preventing and managing the toxicities associated with the combination therapy of ibrutinib and venetoclax in chronic lymphocytic leukaemia |
| title_sort | preventing and managing the toxicities associated with the combination therapy of ibrutinib and venetoclax in chronic lymphocytic leukaemia |
| topic | chronic lymphocytic leukaemia venetoclax ibrutinib cardiovascular events neutropenia |
| url | https://journals.viamedica.pl/acta_haematologica_polonica/article/view/105572 |
| work_keys_str_mv | AT elzbietaiskierkajazdzewska preventingandmanagingthetoxicitiesassociatedwiththecombinationtherapyofibrutinibandvenetoclaxinchroniclymphocyticleukaemia AT krzysztofjamroziak preventingandmanagingthetoxicitiesassociatedwiththecombinationtherapyofibrutinibandvenetoclaxinchroniclymphocyticleukaemia AT tadeuszrobak preventingandmanagingthetoxicitiesassociatedwiththecombinationtherapyofibrutinibandvenetoclaxinchroniclymphocyticleukaemia AT bartoszpuła preventingandmanagingthetoxicitiesassociatedwiththecombinationtherapyofibrutinibandvenetoclaxinchroniclymphocyticleukaemia |